However, the role of anti-TNF-α therapies in increasing the risk of lymphoma has been described and seems clear in patients with autoimmune diseases, such as inflammatory bowel disease [127] or rheumatoid arthritis [128,129]. This evidence concerns the gene TNF and lymphoma.